Study to Evaluate the Safety and Effectiveness of Nextida GC-B on Blood Sugar Control in Adults with Normal Blood Sugar or Prediabetes

What this Trial Is About

Researchers are evaluating the safety and effectiveness of Nextida GC-B, a dietary supplement, on blood sugar control in adults who have normal blood sugar levels or prediabetes. The study aims to understand how Nextida GC-B affects post-meal blood sugar changes over 90 days compared to a placebo. This randomized, triple-blind trial is sponsored by Rousselot BVBA and includes adults with specific body mass index and blood sugar criteria. Participants are randomly assigned to one of two groups. One group takes a 5-gram liquid shot of Nextida GC-B about 30 minutes before two main meals daily, while the other group receives a placebo shot with no active ingredients at the same times. The study lasts 90 days, during which the effects of chronic exposure to Nextida GC-B on blood sugar and related health markers are monitored. During the trial, participants will attend clinic visits and use a continuous glucose monitor to track blood sugar levels. They will complete questionnaires and diaries related to diet, physical activity, and well-being. Researchers will measure a wide range of outcomes including changes in blood sugar control, insulin levels, hormones, inflammation markers, body weight, body composition, skin, hair and nail health, and quality of life. Safety and adherence to the study procedures will be closely observed throughout the 90-day period.

Effect of Chronic Exposure to Nextida GC-B on Glycemic Control in Adults With Normoglycemia or Prediabetes